Pfizer whistleblower case heads to appeals court; Shire inks deal for rare kidney disease program;

Conversation on Twitter :

 @FierceBiotech: From FierceBiotechIT.com: Swedish bioinformatics group grabs $840K to fuel growth, report says. More | Follow @FierceBiotech

 @JohnCFierce: Signs of life? Top 10 biotech IPOs. Special Report | Follow @JohnCFierce

 @RyanMFierce: GSK's SROne leads $35M round for Thrasos Therapeutics for PhII study of kidney injury treatment. Release | Follow @RyanMFierce

> A federal appeals court is slated to hear Pfizer's ($PFE) argument that it should be let off the hook on a jury's award to whistleblower Becky McClain, a lab scientist who claimed that the company had retaliated against her after she claimed that she had become ill after being infected with a virus in the pharma giant's Groton, Connecticut, labs. Pfizer says it never interfered with her speech rights. OSHA found no violations in its inspection of the Groton facilities. Story

> Qiagen has struck a deal to collaborate with Bayer on new diagnostics, starting on drugs that target solid tumors. Report (reg. req.)

> In today's quarterly earnings report, Shire ($SHPG) notes that it struck a deal for a preclinical asset at IGAN Biosciences for IgA nephropathy, a rare kidney disease. Release

Pharma News

@FiercePharma: Novartis puts off restart at Lincoln, Neb., plant... again. Fed-up CEO says no more predictions--Bloomberg. News | Follow @FiercePharma

> What's AZ's new CEO thinking? Let's parse his words. Story

> Gilenya, Afinitor among bright spots in flat Novartis quarter. Article

> Novartis plant delay, vaccine woes steal spotlight. More

Medical Device News

 @FierceMedDev: Alere warned by FDA for cardio Dx quality shortfalls. Item | Follow @FierceMedDev

 @MarkHFierce: A Senate report blasts Medtronic for improperly shaping data regarding its Infuse bone graft, all to boost sales. Story | Follow @MarkHFierce

 @DamianFierce: 2012 was less than a banner year for med device and diagnostic IPOs. We take a look at the numbers: Report | Follow @DamianFierce

> J&J's Ethicon hit with Class I over stapler recall. News

> FDA chides St. Jude over CRM plant. Story

Vaccines News

@AlisonBFierce: U. of Texas at Austin researchers got $6.5M from Dept. of Defense to develop new vaccines for emerging health threats. More | Follow @AlisonBFierce

> Italy bans Novartis influenza vaccines. News

> CDC green-lights GSK's meningitis vaccine for at-risk infants. Item

> HIV antibody development discovery advances vaccine search. Story

> EMA: 'Insufficient' link between narcolepsy and GSK flu vaccine. Report

> Novavax reports positive avian flu vaccine results. Article

Pharma Manufacturing News

> DSM snags another project to feed Australian biologics plant. More

> Novartis CEO defends manufacturing lapses. Article

> FDA group argues for helping poor countries beef up oversight. Story

And Finally… Scientists are working on a new approach that could allow them to correct rare genetic diseases inherited in infants prior to conception. Story

 

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.